Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

PLA2G16 (P53816) - Overview - Molecular Target Synopsis

Protein


PLA2G16, HRAS-like suppressor 3
Enzyme Classification 3.1.1.32
UniProt P53816

Also Known as PA216_HUMAN, PLA2G16, HRASLS3, HREV107

Lipid-modifying enzyme that acts as major regulator of adipocyte lipolysis by catalyzing the release of fatty acids from phospholipids in adipose tissue (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). Shows phospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE) (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). For most substrates, phospholipase A1 activity is much higher than phospholipase A2 activity (PubMed:19047760). Phospholipase activity causes decreased intracellular levels of ether-type lipids, affecting peroxisome metabolism (By similarity). May also have acyltransferase activity: catalyzes both N-acylation of phosphatidylethanolamine to form N-acyl-phosphatidylethanolamine and O-acylation of lyso-phosphatidylcholines to form phosphatidylcholines (PubMed:22605381, PubMed:25383759). The relevance of acyltransferase activity in vivo is however unclear and would require additional evidences (PubMed:22605381, PubMed:25383759). Also has weak lysophospholipase activity., (Microbial infection) Acts as a host factor for picornaviruses: required during early infection to promote viral genome release into the cytoplasm (PubMed:28077878). May act as a cellular sensor of membrane damage at sites of virus entry, which relocalizes to sites of membrane rupture upon virus unfection (PubMed:28077878). Facilitates safe passage of the RNA away from LGALS8, enabling viral genome translation by host ribosome (PubMed:28077878). May also be involved in initiating pore formation, increasing pore size or in maintaining pores for genome delivery (PubMed:28077878). The lipid-modifying enzyme activity is required for this process (PubMed:28077878). Interacts with PPP2R1A; this interaction might decrease PP2A activity.

4Q95
CRYSTAL STRUCTURE OF HRASLS3/LRAT CHIMERIC PROTEIN
RCSB/PDB
Inspect Structure
See all 3D Structures for PLA2G16

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
162ENSG00000176485ENST00000323646, ENST00000415826ENSP00000320337, ENSP00000389124P53816-1
34ENSG00000176485ENST00000540943ENSP00000442576

Sub-cellular localization


UniProt: PLA2G16 is active in the following subcellular-locations: cytoplasm, membrane, perinuclear region, peroxisome membrane.
GO terms: PLA2G16 is active in the following subcellular-locations: cytosol, endoplasmic reticulum, integral component of membrane, perinuclear region of cytoplasm, peroxisomal membrane, peroxisome.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project PLA2G16 has gain in 2 cell-lines, loss in 0 cell-lines and no signal in 1003 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: HT29, KM12, UO_31

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: HUP-T4, 23132/87, CaR-1

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: A549, HSMM, HeLa-S3

(see details)

3D Structures


For PLA2G16 there are:
4 structures (5 chains) solved
1 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis